Medication adherence in schizophrenia: Patient perspectives and the clinical utility of paliperidone ER

Patient Preference and Adherence

Volumn 2, Issue , 2008, Pages 233-240

  Birnbaum, Michael ^a   Sharif, Zafar ^b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

Adherence; Paliperidone; Pharmacokinetics; Schizophrenia

Indexed keywords

EID: 77956566534     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S3346     Document Type: Review

References (39)

1. Ascher-Svanum H, Faries DE, Zhu B, et al. 2006. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry, 67:453-60.
2. Bebbington P.E. 1995. The content and context of compliance. Int Clin Psychopharmacol, 9(Suppl 5):41-50.
3. Buckley P. F, Wirshing DA, Bhushan P, et al. 2007. Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs, 21:129-41.
4. Byerly M. J, Thompson A, Carmody T, et al. 2007. Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv, 58:844-7.
5. Cournos F., McKinnon K, Sullivan G. 2005. Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus. J Clin Psychiatry, 66(Suppl)6:27-33.
6. Davidson M., Emsley R, Kramer M, et al. 2007. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.[erratum appears in Schizophr Res. 2007 Nov; 96(1-3):273-4]. Schizophr Res, 93:117-30.
7. De Leon J, Susce MT, Pan R-M, et al. 2005. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry, 66:15-27.
8. Degmecic D., Pozgain I, Filakovic P. 2007. Psychoeducation and compliance in the treatment of patients with schizophrenia. Coll Antropol, 31:1111-5.
9. Dixon L. 1999. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res, 35(Suppl): S93-100.
10. Docherty J. P, Kozma C, Grogg A, et al. 2002. Antipsychotic maintenance in schizophrenia: Partial compliance and clinical outcome. Am Coll Neuropsychopharmacol, 179.
11. Dolder C. R, Lacro JP, Dunn LB, et al. 2002. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry, 159:103-8. [erratum Am J Psychiatry, 159:514].
12. Dolder C. R, Lacro JP, Leckband, et al. 2003. Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol, 23:389-99.
13. Duncan J. C, Rogers R. 1998. Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders. J Forensic Sci, 43:1133-7.
14. Eerdekens E., et al. 2006. US Psychiatric and Mental Health Congress. 16-19 Nov 2006, New Orleans, USA. Poster 335.
15. Greenberg R.N. 1984. Overview of patient compliance with medication dosing: a literature review. Clin Ther, 6:592-9.
16. Haro J. M, Salvador-Carulla L. 2006. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs, 20:293-301.
17. Jeste S. D, Patterson TL, Palmer BW, et al. 2003. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr Res, 63:49-58.
18. Kamali M., Kelly BD, Clarke M, et al. 2006. A prospective evaluation of adherence to medication in first episode schizophrenia. Eur Psychiatry, 21:29-33.
19. Kane J., Canas F, Kramer M, et al. 2007. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res, 90:147-61.
20. Karlsson P., Dencker S, Nyberg S, et al. 2006. Pharmacokinetics and dopamine D2 and Serotonin 5-HT2A receptor occupancy of paliperidone in Healthy Subjects: Two open-label single-dose studies. Clin Pharmacol Ther, 79:74.
21. Lacro J. 2006. Optimizing adherence to treatment in patients with schizophrenia. Behav Healthc, 26:38-42.
22. Lacro J. P, Dunn LB, Dolder CR, et al. 2002. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry, 63:892-909.
23. Lehman A. F, Steinwachs DM. 1998. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull, 24:1-10.
24. Lieberman J. A, Koreen AR, Chakos M, et al. 1996. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry, 57(Suppl 9):5-9.
25. Lieberman J. A, Stroup TS, McEvoy JP, et al.; and Clinical Antipsychotic Trials of Intervention Effectiveness, I. 2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.[see comment]. N Engl J Med, 353:1209-23.
26. Liu-Seifert H, Adams DH, Kinon BJ. 2005. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Medicine, 3:21.
27. Marder S. R, Kramer M, Ford L, et al. 2007. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry, 62:1363-70.
28. McGrath J, Scheldt S, Welham J, et al. 1997. Performance on tests sensitive to impaired executive ability in schizophrenia, mania and well controls: acute and subacute phases. Schizophr Res, 26:127-37.
29. Menzin J., Boulanger L, Friedman M, et al. 2003. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv, 54:719-23.
30. Paliperidone (Prescribing Information). 2008. URL: http://www.fda.gov/ cder/foi/label/2006/021999lbl.pdf. Accessed April 4 2008.
31. Paliperidone Product Monograph, ER. 2007 http://www.janssen-ortho. com/JOI/pdf_files/Invega_E.pdf. Accessed April 4 2008, page 22.
32. Piette J. D, Heisler M, Ganoczy D, et al. 2007. Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension. Psychiatr Serv, 58:207-12.
33. Robinson D., Woerner MG, Alvir JM, et al. 1999. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry, 56:241-7.
34. Van Putten T. 1978. Drug refusal in schizophrenia: causes and prescribing hints. Hosp Community Psychiatry, 29:110-2.
35. Velligan D. I, Lam Y-WF, Glahn DC, et al. 2006. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull, 32:724-42.
36. Weiden P., Dixon L, Frances A. 1991. Neuroleptic noncompliance in schizophrenia, in Advances in Neuropsychiatry and Psychopharmacology. Schizophr Res, 1:285-96.
37. Weiden P., Rapkin B, Mott T, et al. 1994. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull, 20:297-310.
38. Weiden P. J, Kozma C, Grogg A, et al. 2004. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia.[see comment]. Psychiatr Serv, 55:886-91.
39. Wyatt R.J. 1991. Neuroleptics and the natural course of schizophrenia. Schizophr Bull, 17:325-51.